Company / R&D per Share
Dianthus Therapeutics, Inc. /DE/ R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.68
FY2025
5-year range
$0.85 / $33.61
FY2021-FY2025
Trend
+111.2%
vs FY2024
Sector context
#39 of 208
Health Care
What the data says
Dianthus Therapeutics, Inc. /DE/'s r&d per share of $4.68 is higher than 81% of companies in the Health Care sector (FY2025). R&D per Share returned to growth in FY2025 after 2 years of decline, reaching $4.68.
Based on SEC 10-K filings.
4.68 in FY2025 with a 5-year CAGR of +32.4%. Top quartile in the Health Care sector.
Declined from $6.37 to $4.68 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -48.2%
- 5-Year CAGR
- +32.4%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 208This company $4.68 Sector average $12.19
▼
-61.6% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 111.2% year-over-year.
- Ranks #39 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2016.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.68 | +111.2% |
| FY2024 | $2.22 | -65.2% |
| FY2023 | $6.37 | -81.0% |
| FY2022 | $33.61 | +3848.5% |
| FY2021 | $0.85 | -26.1% |
| FY2020 | $1.15 | -35.2% |
| FY2019 | $1.78 | -89.9% |
| FY2018 | $17.58 | +17.0% |
| FY2017 | $15.02 | -61.2% |
| FY2016 | $38.70 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026